Wells Fargo Report Says GLP-1s Reducing Certain Surgeries

Robin Wenzel, head of Wells Fargo Industry Insights, said that the rise of GLP-1s has brought down the rate of bariatric surgery by more than 30%, providing a less invasive 'pharmaceutical offramp' for weight management. Wenzel said GLP-1 use rose… Robin Wenzel, head of Wells Fargo Industry Insights, said that the rise of GLP-1s has brought down the rate of bariatric surgery by more than 30%, providing a less invasive 'pharmaceutical offramp' for weight management. Wenzel said GLP-1 use rose 120% between 2022 and 2024 and that it offers the parts of the healthcare industry an opportunity to turn to helping patients manage medication or their side effects. (Source: Bloomberg)